Antibody-Drug Conjugates (ADCs)
Integrated ADC Development from Discovery to IND
Antibody-drug conjugates combine a targeting antibody, a linker, and a therapeutic payload into a single complex molecule. The performance of each component – and the relationships among them – can affect binding, internalization, stability, payload release, exposure, efficacy, and safety.
WuXi Biology and Testing integrates ADC molecule preparation, discovery biology, pharmacology, DMPK, bioanalysis, safety assessment, and regulatory strategy from early design through IND-enabling studies. Coordinated planning helps you evaluate the intact conjugate, its individual components, and the analytes or risks that emerge as the molecule changes in biological systems.
ADC Experience Across Discovery and Development
ADC Molecules Prepared
Attachment-Site Series Assembled
ADC Candidates Supported Through IND-Enabling
Why ADCs Need a Modality-Specific Strategy
ADC performance depends on the combined behavior of the antibody, linker, payload, attachment site, conjugation profile, and drug-to-antibody ratio. Development strategies must account for target binding and internalization, conjugate integrity, payload release, tissue distribution, immunogenicity, and target- or payload-related safety risks.
No single assay can answer every question. A stage-based strategy aligns discovery assays, pharmacology, DMPK, bioanalysis, and safety assessment with the decisions needed for candidate selection and IND readiness.
Stage-Based ADC Challenges and Solutions
Challenges
- Balancing antibody specificity and internalization with linker stability, payload potency, conjugation, drug-to-antibody ratio, and developability.
Solutions
- Combine antibody evaluation with payload and linker synthesis, attachment-site options, ADC preparation, analytical characterization, and binding and internalization assays to guide candidate design.
Challenges
- ADC format, linker stability, payload release, and conjugate integrity can alter biological activity, bystander effects, and off-target risk.
Solutions
- Use stability and release profiling with binding, internalization, trafficking, cytotoxicity, cell-cycle, apoptosis, bystander, ADCC, and ADCP assays supported by orthogonal methods.
Challenges
- Antigen expression, model biology, species cross-reactivity, and tumor versus systemic exposure can limit translation.
Solutions
- Combine relevant CDX and PDX models with efficacy, PK/PD, tissue distribution, biodistribution, species selection, and surrogate approaches when appropriate.
Challenges
- ADCs generate multiple relevant analytes, changing drug-to-antibody ratio, low payload concentrations, catabolites, and matrix interference.
Solutions
- Use ligand-binding, LC-MS/MS, and hybrid immunocapture methods to measure intact or conjugated antibody, total antibody, free payload, relevant catabolites, drug-to-antibody ratio, immunogenicity, and biomarkers.
Challenges
- Target-mediated toxicity, antibody-related effects, payload toxicity, premature linker release, species relevance, and immunogenicity may require different lines of evidence.
Solutions
- Integrate tissue cross-reactivity, dose-range finding, repeat-dose toxicology, safety pharmacology, payload-focused genetic toxicology when appropriate, ADA/NAb assessment, pathology, exposure, and toxicokinetics.
Challenges
- The antibody, linker, payload, and conjugation strategy create a combined benefit-risk profile that must be supported by coherent pharmacology, DMPK, bioanalysis, and safety data.
Solutions
- Use integrated study planning, regulatory consultation aligned with ICH guidance and regional expectations, coordinated reporting, and cross-functional data interpretation to support submission readiness.
ADC Molecule Preparation and Characterization
Support payloads and payload analogs, linker chemistries, attachment-site strategies, conjugation, ADC molecule preparation, and scale-up. Analytical characterization can examine conjugate integrity, heterogeneity, aggregation, attachment sites, and drug-to-antibody ratio to help compare candidates and identify development risks.
Translational Assays and Tumor Models
Evaluate target binding, antibody internalization, cell viability, bystander killing, cell-cycle effects, apoptosis, ADCC, and ADCP using complementary cellular assays. Xenograft models across multiple targets and tumor types can support studies of ADC biodistribution, efficacy and bystander killing evaluation. Unique ADC related resistant models are important tools to differentiate drug value.
Bioanalysis and Data Continuity
ADC methods evolve as a candidate advances. Early assays may support molecule comparison, while later studies require qualified or validated methods, controlled sample handling, and coordinated measurement of the intact conjugate, antibody-related analytes, payload, catabolites, biomarkers, and immunogenicity.
Planning these transitions early helps align pharmacology, DMPK, bioanalysis, and safety data, ensuring each stage builds on the last rather than creating avoidable assay gaps or rework.
Related Services
Connect molecule design, biological activity, disposition, measurement, and safety in a coordinated antibody-drug conjugate development strategy.
Discovery Biology
Evaluate target binding, internalization, cytotoxicity, bystander activity, immune effector function, resistance, and tumor-model efficacy.
Learn More
DMPK
Characterize linker stability, payload release, pharmacokinetics, tissue distribution, biotransformation, & exposure-response relationships.
Learn More
Bioanalysis
Measure conjugated and total antibody, free payload, catabolites, drug-to-antibody ratio, immunogenicity, and biomarkers.
Learn More
Safety Assessment
Assess target-mediated, linker-related, payload-specific, immunogenicity, and off-target risks through IND-enabling studies.
Learn More
Discuss Your Program with Us
Share your development goals and key challenges with our experts to define the right path forward.
Frequently Asked Questions
An antibody-drug conjugate is a targeted therapeutic composed of an antibody, a linker, and a payload. The antibody recognizes the target, while the linker connects the payload and helps control when and where it is released.
ADC performance can be influenced by target expression, antibody affinity and internalization, linker stability, payload potency, attachment site, drug-to-antibody ratio, conjugate integrity, tissue distribution, and behavior in biological matrices.
Drug-to-antibody ratio describes the average number of payload molecules attached to each antibody. It can affect potency, stability, pharmacokinetics, heterogeneity, and safety, so it should be interpreted alongside other molecule attributes.
An ADC development strategy may include target-binding and internalization assays, cytotoxicity and bystander assays, efficacy models, pharmacokinetics, linker and payload-release studies, tissue distribution, multi-analyte bioanalysis, immunogenicity, and modality-specific safety assessment.
ADCs can generate several relevant analytes, including conjugated antibody, total antibody, free payload, and payload-containing catabolites. Ligand-binding, LC-MS/MS, and hybrid methods provide complementary measurements that support a more complete understanding of exposure and disposition.



